Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epil...

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $50 price target.

Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial f...

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $...

Cantor Fitzgerald analyst Charles Duncan reiterates Harmony Biosciences (NASDAQ:HRMY) with a Overweight and maintains $49 pr...

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $50 price target.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, ma...